-
公开(公告)号：US20210156875A1
公开(公告)日：2021-05-27
申请号：US17161998
申请日：2021-01-29
Applicant: Roche Diagnostics Operations, Inc. , Universitaet Maastricht , Academisch Ziekenhuis Maastricht
Inventor： Johann Karl , Peter Kastner , Roberto Latini , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , Andre Ziegler , Manuel Dietrich , Jennifer Meessen , Ulrich Schotten
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
-
公开(公告)号：US20190277861A1
公开(公告)日：2019-09-12
申请号：US16420385
申请日：2019-05-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Ursula-Henrike Wienhues-Thelen , Dirk Block , Christian Zaugg , Hans-Peter Brunner , James Januzzi , Andre Ziegler , Julian Braz , Thomas Dieterle , Edelgard Kaiser
IPC: G01N33/68
Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
-
公开(公告)号：US20180231570A1
公开(公告)日：2018-08-16
申请号：US15943104
申请日：2018-04-02
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Andrea Horsch , Birgit Klapperich , Dirk Block , Alfred Engel , Johann Karl , Rosemarie Kientsch-Engel , Ekaterina Manuilova , Christina Rabe , Sandra Rutz , Monika Soukupova , Ursula-Henrike Wienhues-Thelen , Peter Kastner , Edelgard Anna Kaiser
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/68 , G01N33/74 , G01N2333/47 , G01N2333/8139 , G01N2800/347 , G01N2800/50
Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.
-
公开(公告)号：US20170115294A1
公开(公告)日：2017-04-27
申请号：US15399801
申请日：2017-01-06
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Norbert Wild , Ursula Garczarek , Andrea Geistanger , Herbert Andres , Marie-Luise Hagmann , Johann Karl , Freidemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thierolf
IPC: G01N33/574
CPC classification number: G01N33/57419 , C12Q1/6886 , G01N2333/4727 , G01N2333/805 , G01N2333/8146 , G01N2333/9121
Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
-
公开(公告)号：US20160377625A1
公开(公告)日：2016-12-29
申请号：US15259392
申请日：2016-09-08
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Markus Roessler , Johann Karl , Julia Riedlinger , Ingo Lindner , Michael Tacke
IPC: G01N33/574
CPC classification number: G01N33/57488 , G01N33/57423 , G01N33/57484 , G01N2333/475 , G01N2800/52
Abstract: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
Abstract translation: 披露了一种有助于评估癌症的方法。 更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。 进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。 例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20150056642A1
公开(公告)日：2015-02-26
申请号：US14533362
申请日：2014-11-05
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Julia Riedlinger , Markus Roessler
IPC: G01N33/68
CPC classification number: G01N33/6884 , G01N33/6893 , G01N2333/47 , G01N2800/122 , G01N2800/60
Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ARMET in said sample in vitro.
Abstract translation: 一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。 本公开还涉及通过在体外测量所述样品中的蛋白质ARMET来评估来自个体的样品的COPD的方法。
-
公开(公告)号：US11946938B2
公开(公告)日：2024-04-02
申请号：US16899629
申请日：2020-06-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Johann Karl , Peter Kastner , Vinzent Rolny , Andre Ziegler , David Conen
CPC classification number: G01N33/6893 , G01N2333/4745 , G01N2333/515 , G01N2800/326 , G01N2800/50
Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.
-
18.发明申请公开(公告)号：US20200300869A1
公开(公告)日：2020-09-24
申请号：US16899629
申请日：2020-06-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Johann Karl , Peter Kastner , Vinzent Rolny , Andre Ziegler , David Conen
IPC: G01N33/68
Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.
-
公开(公告)号：US20190162737A1
公开(公告)日：2019-05-30
申请号：US16264779
申请日：2019-02-01
Inventor： Johann Karl , Peter Kastner , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Andre Ziegler , Manuel Dietrich , Ulrich Schotten , Vinzent Rolny
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
-
公开(公告)号：US20180364248A1
公开(公告)日：2018-12-20
申请号：US16110687
申请日：2018-08-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Martin Hund , Edelgard Anna Kaiser , Ursula-Henrike Wienhues-Thelen , Dirk Block , Johann Karl
IPC: G01N33/68
Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.021 seconds)
